savolitinib – Patient Worthy

Photo by Robina Weermeijer on Unsplash

ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma

Post author:Jessica Lynn
Post published:November 30, 2021
Post category:Papillary renal cell carcinoma Renal Cell Carcinoma

According to a news release, researchers from biopharmaceutical company HUTCHMED and pharmaceutical company AstraZeneca launched, at the onset of November 2021, the Phase 3 SAMETA clinical trial. During the trial,…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More